Accreditation
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Conexiant Education. The Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 17.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 17.75 contact hours. Designated contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses will be available closer to the event.
Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 17.75 contact hour(s) (1.775 CEUs) of the Accreditation Council for Pharmacy Education.
Type of Activity: Application
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 17.75 Interprofessional Continuing Education (IPCE) credit for learning and change.
Continuing Physician Assistant Education
Postgraduate Institute for Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 17.75 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Continuing Education Credit
To be eligible for credit and to receive a certificate, participants must complete the full activity and submit a completed evaluation form. This activity will also be available in an enduring (on demand) format from October 28 through December 31, 2026. Participants may claim continuing education credit for either format by completing all required components, including the post activity evaluation. All evaluations must be submitted online by December 31, 2026.
Intended Audience
The intended audience for this conference is nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, hematology/oncology nurses, pharmacists, and clinicians who specialize in the field of oncology.
Learning Objectives
- Summarize recent drug approvals, expanded indications, and emerging therapies across solid tumor and hematologic malignancies, including mechanisms of action and supporting clinical trial data.
- Develop evidence-based treatment plans that incorporate sequencing strategies, biomarker-driven therapy selection, and management of adverse events across the cancer continuum.
- Integrate complex and novel therapeutic approaches, including bispecific antibodies, antibody-drug conjugates, and radiation and surgical oncology considerations, into safe, coordinated, patient-centered care.
- Apply communication, leadership, and practice skills to support shared decision-making and patient advocacy as part of oncology care team.
Conference Chair
Amber Koehler, PA-C, MS
Mayo Clinic
Planning Committee
Lorinda A. Coombs, PhD, CNS, FNP-BC, AOCNP®
University of North Carolina Chapel Hill School of Nursing and Lineberger Comprehensive Cancer Center
Rose DiMarco, PharmD, BCPS, BCOP
Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO
Cleveland Clinic
Andrew Guinigundo, MSN, RN, CNP, ANP-BC, OHC, FAPO
Cincinnati Cancer Advisors
Kelly Haviland, PhD, RN, MSN, FNP-BC, TGNB-C
New York University
Jillian Hunt, MSN, APRN, FNP-C, AOCNP
Cincinnati Cancer Advisors
Yi (Lisa) Hwa, APRN, DNP, CNP, FAPO
Mayo Clinic
Heather Koniarczyk, MSN, APRN-CNP, AOCNP®, FAPO
Conexiant & APSHO
Lisa Kottschade, APRN, MSN, CNP, FAPO
Mayo Clinic
Haleigh E. Mistry, MA, PA-C
MD Anderson Cancer Center
Amy Pierre, MSN, ANP-BC
Memorial Sloan Kettering Cancer Center & Flatiron Health
Kate Taucher, PharmD, MHA, BCOP, FAPO
UCHealth Memorial Hospital
Tammy Triglianos, DNP, ANP-BC, AOCNP
Conexiant
Steven Wei, EdD, MPH, MS, PA-C, DFAAPA
MD Anderson Cancer Center
Wendy Vogel, MSN, FNP, AOCNP®, FAPO
Conexiant & APSHO
Disclosure of Financial Relationships
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified financial relationships are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
In accordance with Joint Accreditation requirements, the following individuals have disclosed relevant financial relationships with ineligible companies:
- Lisa Hwa Christenson, DNP has disclosed financial relationships with GSK, J&J, Pfizer, Regeneron, and Sanofi.
- Rose DiMarco, PharmD, BCPS, BCOP has disclosed financial relationships with Bristol Myers Squibb (BMS), Gilead, IO Biotech, Jazz, Lilly, Sanofi, and Urogen.
- Andrew Guinigundo, MSN, RN, CNP, ANP-BC, FAPO has disclosed financial relationships with Amgen, Astellas, AstraZeneca, and Pfizer.
- Lisa Kottschade, APRN, MSN, CNP has disclosed financial relationships with Immunocore and Repliimune.
- Haleigh Mistry, MS, PA-C has disclosed financial relationships with AbbVie, Curio Science, DAVA Oncology, GenMab, Horizon CME-APPOS, and Recordati Rare Diseases.
- Kate Taucher, PharmD has disclosed financial relationships with ACCC, Advarra, ASCO, Genmab, and MECC.